이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Coloplast 과거 수익 실적
과거 기준 확인 2/6
Coloplast은 연평균 4.9%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 수입이 증가했으며, 연간 6%였습니다. 매출은 연평균 8.3%의 비율로 증가했습니다. Coloplast의 자기자본이익률은 30.6%이고 순이익률은 19.5%입니다.
주요 정보
4.9%
수익 성장률
4.5%
EPS 성장률
| Medical Equipment 산업 성장 | -1.7% |
| 매출 성장률 | 8.3% |
| 자기자본 수익률 | 30.6% |
| 순이익 | 19.5% |
| 다음 실적 업데이트 | 20 Aug 2024 |
최근 과거 실적 업데이트
Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations
May 21
Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues
Nov 16Recent updates
These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Jun 29Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations
May 21Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00
May 10Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report
May 09A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)
Apr 26There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price
Apr 08Is Coloplast (CPH:COLO B) A Risky Investment?
Mar 21Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)
Jan 09Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings
Dec 22These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Dec 04Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues
Nov 16A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)
Sep 30Is Coloplast (CPH:COLO B) A Risky Investment?
Jun 28Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price
Jun 10Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Mar 22Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 01These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Dec 14Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Nov 26Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being
Nov 25Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 11With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case
Oct 25Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)
Aug 26These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Jul 27Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching
Jul 12Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?
May 23Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00
May 08Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly
Apr 13Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock
Mar 29Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate
Feb 12Coloplast (CPH:COLO B) Could Easily Take On More Debt
Jan 12Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?
Dec 28Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All
Nov 25A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)
Oct 31Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly
Oct 02Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?
Sep 16Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?
Aug 02Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Jul 01Does Coloplast (CPH:COLO B) Deserve A Spot On Your Watchlist?
Jun 16수익 및 비용 분석
수익 및 비용 분석
Coloplast 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 31 Mar 24 | 25,526 | 4,965 | 9,252 | 901 |
| 31 Dec 23 | 25,001 | 4,868 | 8,934 | 889 |
| 30 Sep 23 | 24,500 | 4,783 | 8,632 | 872 |
| 30 Jun 23 | 24,333 | 4,784 | 8,581 | 858 |
| 31 Mar 23 | 24,074 | 4,801 | 8,550 | 864 |
| 31 Dec 22 | 23,515 | 4,626 | 8,272 | 877 |
| 30 Sep 22 | 22,579 | 4,706 | 7,800 | 866 |
| 30 Jun 22 | 21,620 | 4,781 | 7,336 | 856 |
| 31 Mar 22 | 20,606 | 4,746 | 6,828 | 819 |
| 31 Dec 21 | 19,857 | 4,896 | 6,446 | 774 |
| 30 Sep 21 | 19,426 | 4,825 | 6,249 | 755 |
| 30 Jun 21 | 18,916 | 4,561 | 6,098 | 723 |
| 31 Mar 21 | 18,500 | 4,304 | 5,938 | 720 |
| 31 Dec 20 | 18,570 | 4,241 | 5,993 | 725 |
| 30 Sep 20 | 18,544 | 4,197 | 6,086 | 708 |
| 30 Jun 20 | 18,572 | 3,949 | 6,113 | 698 |
| 31 Mar 20 | 18,752 | 4,020 | 6,199 | 691 |
| 31 Dec 19 | 18,330 | 3,974 | 6,118 | 680 |
| 30 Sep 19 | 17,939 | 3,873 | 5,970 | 692 |
| 30 Jun 19 | 17,555 | 4,119 | 5,753 | 686 |
| 31 Mar 19 | 17,181 | 3,999 | 5,626 | 671 |
| 31 Dec 18 | 16,815 | 3,896 | 5,488 | 663 |
| 30 Sep 18 | 16,449 | 3,845 | 5,375 | 640 |
| 30 Jun 18 | 16,195 | 3,816 | 5,315 | 619 |
| 31 Mar 18 | 15,882 | 3,778 | 5,211 | 605 |
| 31 Dec 17 | 15,728 | 3,791 | 5,104 | 594 |
| 30 Sep 17 | 15,528 | 3,797 | 4,994 | 574 |
| 30 Jun 17 | 15,287 | 3,211 | 4,880 | 565 |
| 31 Mar 17 | 15,061 | 3,279 | 4,785 | 551 |
| 31 Dec 16 | 14,780 | 3,264 | 4,731 | 521 |
| 30 Sep 16 | 14,681 | 3,143 | 4,693 | 509 |
| 30 Jun 16 | 14,563 | 1,297 | 4,690 | 494 |
| 31 Mar 16 | 14,417 | 1,028 | 4,627 | 477 |
| 31 Dec 15 | 14,264 | 927 | 4,583 | 458 |
| 30 Sep 15 | 13,909 | 899 | 4,488 | 442 |
| 30 Jun 15 | 13,502 | 3,162 | 4,343 | 437 |
| 31 Mar 15 | 13,096 | 3,241 | 4,220 | 418 |
| 31 Dec 14 | 12,666 | 2,407 | 4,088 | 406 |
| 30 Sep 14 | 12,428 | 2,390 | 4,002 | 390 |
| 30 Jun 14 | 12,184 | 2,298 | 3,959 | 375 |
| 31 Mar 14 | 12,008 | 2,220 | 3,944 | 370 |
| 31 Dec 13 | 11,833 | 2,874 | 3,889 | 382 |
| 30 Sep 13 | 11,635 | 2,711 | 3,854 | 380 |
양질의 수익: COLO B 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: COLO B 의 현재 순이익 이익률 (19.5%) 작년보다 낮습니다 (19.9%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: COLO B 의 수입은 지난 5년 동안 매년 4.9% 씩 증가했습니다.
성장 가속화: 지난 1년간 COLO B 의 수익 증가율( 3.4% )은 5년 평균( 4.9% 보다 낮습니다. 년도).
수익 대 산업: 지난 1년간 COLO B 수익 성장( 3.4% )은 Medical Equipment 업계 4.9% 능가하지 못했습니다. 4.9%.
자기자본 수익률
높은 ROE: COLO B 의 자본 수익률( 30.65% )이 높음이지만, 이 지표는 높은 부채 수준으로 인해 왜곡됩니다.